CRL
🔒 LOCKEDCharles River Laboratories Inte
🔒 Unlock Full Analysis
Sign in and use 1 credit to see AI verdict, intrinsic value, SWOT analysis, and all premium insights.
AI Executive Summary
Charles River Laboratories is a leading provider of essential products and services to help pharmaceutical and biotechnology companies accelerate their research and drug development efforts, and is expected to grow with the increasing R&D spending in the healthcare industry.
The Business DNA
Charles River Laboratories provides research models, discovery, and safety assessment services, along with manufacturing support for the pharmaceutical and biotechnology industries. The company benefits from long-term relationships with its clients and a diversified service portfolio. Its competitive position is bolstered by its global presence and expertise in preclinical and clinical research. They operate in a highly regulated industry, requiring significant expertise and infrastructure.
Financial Health
Valuation Analysis
The current price of CRL is around $201, while the average target price is $215. The forward PE suggests a reasonable valuation, but the negative PE ratio and PEG ratio make it difficult to assess the company's growth prospects using these metrics. The price-to-sales ratio is moderate, and the price-to-book ratio is relatively low.
Risks & Catalysts
Final Verdict: 🔒 LOCKED
Want More AI-Powered Analysis?
Get unlimited stock analyses, portfolio tracking, and real-time alerts
Related Stock Analyses
This analysis is generated by AI and should not be considered financial advice. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Last updated: 3/17/2026